My education regarding our miracle molecule is on

My education regarding our miracle molecule is on a continuing process, so forgive me if these questions are simplistic. I have two Questions for the Board and Ohm:

(1) Is there a reason why TAS-102 and Bevacizumab is being used in conjunction with Leronlimab instead of a checkpoint inhibitor? Is it because TAS-102 and Bevacizumab is the standard of care? Or maybe because we didn't realize the novel MOA until just recently?

(2) If Leronlimab helps the standard of care and raises the PD-L1 but the treatment fails, can they continue with Leronlimab and add a checkpoint inhibitor like Keytruda (which is approved for colon and rectal cancer treatment) as a second or follow-on treatment?

In Question 2 I'm thinking of a situation where PD-L1 is raised (as measured by Creatv Bio's test) and CTC and CAMLs are reduced but the disease has not entirely been mitigated.

Thanks and remember we are actually in the early innings of the new strategy that Dr J and the capable management team has come up with.
Having a miracle molecule that can increase PD-L1 and reduce CTC and CAMLs (and coupled with that, have the PD-L1 measured by Creatv Bio's new blood test) is going to amount to a huge advancement in the field.

CytoDyn and Dr J and team are making all the right strategic moves.
And our Long investments make a difference.
Keep on keeping on